Adamax Peptide – Advanced Nootropic Research Peptide for Cognitive Studies

Adamax Peptide (N-Acetyl Semax Adamantyl) – Cognitive Enhancement Research Compound

Adamax is a synthetic peptide derivative and an advanced analogue of Semax, developed as a nootropic and neuroprotective research compound . Often described as Semax modified with both N-terminal acetylation and a C-terminal adamantyl group, these structural modifications significantly enhance its stability, lipophilicity, and ability to cross the blood-brain barrier . Adamax is considered the most potent among Semax derivatives and is a valuable research tool for investigating cognitive enhancement, neuroprotection, and neuroplasticity . This research-grade peptide is strictly for laboratory investigation and is not intended for human consumption.

Key Factual Details

Mechanism of Action & Research Applications

Enhanced BDNF Signaling: Adamax works by increasing Brain-Derived Neurotrophic Factor (BDNF) levels and improving the sensitivity of TrkB receptors, particularly in the hippocampus, a region vital for memory and learning . This interaction promotes improved cognitive functions, such as memory retention, focus, and overall mental clarity .

Structural Modifications for Enhanced Potency: The N-terminal acetyl group and C-terminal adamantyl modification improve stability and resistance to enzymatic degradation. The adamantane moiety, in particular, allows for easier blood-brain barrier penetration, resulting in greater potency than standard Semax .

Research Applications:

• Cognitive Enhancement Studies: Investigating memory, focus, and executive function

• Neuroprotection Research: Exploring neuron shielding and damage prevention mechanisms

• Neurogenesis Studies: Examining neuron regeneration and brain plasticity

• Neurodegenerative Disease Models: Research into cognitive decline and neurological conditions

Research Parameters

All dosages are for in-vitro and preclinical research use only and are not intended for human consumption.

Reconstitution Protocol :

• Add 3.0 mL bacteriostatic water to 10 mg vial → final concentration of ~3.33 mg/mL

Research Dosing Regimen :

• Starting Dose: 300 µg daily (Weeks 1-2)

• Mid-Range Dose: 500–750 µg daily (Weeks 3-6)

• Maintenance Range: 500–1,000 µg once daily

• Cycle Length: 8-12 weeks, followed by an equal off-cycle period

• Administration: Subcutaneous injection

Storage:

• Lyophilized powder: Store at -20°C

• Reconstituted solution: Refrigerate at 2-8°C, use within 1-2 weeks; avoid freeze-thaw cycles